ARCT-2138

Arcturus Therapeutics, Inc. · Phase 1 active Biologic Quality 0/100

At a glance

Generic name	ARCT-2138
Also known as	Self-Amplifying RNA seasonal Influenza vaccine
Sponsor	Arcturus Therapeutics, Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ARCT-2138 CI brief — competitive landscape report
ARCT-2138 updates RSS · CI watch RSS
Arcturus Therapeutics, Inc. portfolio CI